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Abstract Due to controversy about the involvement of
Dync1h1 mutation in pathogenesis of motor neuron dis-
ease, we investigated expression of tau protein in trans-
genic hybrid mice with Dync1h1 (so-called Cra1/?),
SOD1G93A (SOD1/?), double (Cra1/SOD1) mutations
and wild-type controls. Total tau-mRNA and isoforms 0, 1
and 2 N expression was studied in frontal cortex, hippo-
campus, spinal cord and cerebellum of presymptomatic and
symptomatic animals (age 70, 140 and 365 days). The
most signiﬁcant differences were found in brain cortex and
cerebellum, but not in hippocampus and spinal cord. There
were less changes in Cra1/SOD1 double heterozygotes
compared to mice harboring single mutations. The differ-
ences in total tau expression and in proﬁle of its isoforms
between Cra1/? and SOD1/? transgenics indicate a dis-
tinct pathogenic entity of these two conditions.
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Introduction
Intracellular transport along microtubules is especially
important in motor neurons, the axons of which may reach
the length of over one meter [1]. The major components of
this transport are microtubules, actin ﬁlaments and motor
proteins. Many studies indicate an impairment of axonal
transport in motor neuron diseases. Cytoplasmic dynein is
one of microtubule associated proteins (MAPs) responsible
for axonal transport toward the minus end of microtubules
[2, 3]. It is a large multi-subunit protein complex (MW
about 1.5 MD) formed of two identical heavy chains (MW
532 kD), few intermediate chains (MW 74 and 53–59 kD),
and several light chains [4]. Heavy chains bind ATP, a
source of energy for dynein movement along microtubules
and the intermediate chains probably anchor dynein to its
cargo. Heavy chains are encoded by a 78-exon gene,
Dync1h1. Knocking out the Dync1h1 results in early
embryonic lethality in mice [5]. Mice with an autosomal
dominant missense point mutations in the Dnchc1 gene
show a progressive limb paresis. Due to abnormal body
twisting and cramping of the hindlimbs when suspended by
tail they were called Legs at odd angles (Loa) and
Cramping 1 (Cra1) mice. On molecular level Cra1 mice
show defects in dynein complex resulting in an impaired
retrograde axonal transport [6–8]. The exchange of tyrosine
to cysteine (Cra1: 1051VWLQCQCLW1059; wild type:
1051VWLQYQCLW1059) within the dynein heavy chain
leads to an age related progressive degeneration of the
motor neurons. The phenotype of Cra1 mice is similar (but
milder) to transgenic mice with SOD1G93A mutation,
recognized as the animal model of amyotrophic lateral
sclerosis [9]. In contrast to SOD1 mice, the life span of
Cra1 and Loa heterozygotes remains almost unchanged
compared to wild-type animals [8]. In motor neurons of
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port appear already during embryonic development.
Unexpectedly, crossing SOD1G93A mice with Loa or Cra1
delays the disease progression and signiﬁcantly increases
the life span of SOD1 double heterozygotes (Loa/SOD1
and Cra1/SOD1) [10]. Thus, mutations in the Dnc1h1 gene
appear to inﬂuence the progression of motor neuron
degeneration and SOD1G93A-toxicity [10, 11]. However,
there are publications that call in question the above
opinion [12–15]. Dupuis et al. (2009) proved that Cra/?
heterozygotes do not display typical feature of motor
neuron disease, even in aged animals, but instead they
develop an early-onset sensory neuropathy.
Beside the main motor proteins, including dynein/dyn-
actin complex and kinesins, there are other motors involved
in the axonal transport. Among them, the tau protein,
responsible for polymerization and stabilization of micro-
tubules in neurons, astrocytes and oligodendrocytes, as
well as their organization into bundles [16–18]. Tau also
enhances the attachment of dynein/dynactin complex to
microtubules by binding proper N-terminal part to the
C-terminus of the 150 subunit of dynactin [19]. The
mutation of the latter was found responsible for the motor
neuron disease in humans [20]. Human tau gene contains
16 exons, but tau primary transcript present in the central
nervous system consists of 13 exons [21–23]. Exons 2, 3
and 10 undergo alternative splicing giving rise to six dif-
ferent mRNAs translated into six different protein iso-
forms. These isoforms differ from each other by the
presence or absence of three inserts encoded by exons 2
and 3 at the N-terminal part, and exon 10 at the C-terminal
part. The 0 N tau isoform does not contain products of
exons 2 and 3 (-2 -3), whereas isoform 1 N contains an
insert encoded by exon 2 (?2–3), and isoform 2 N an insert
encoded by exons 2 and 3 (?2 ?3) [21]. The product of
exon 10 (R2 domain) is present at the C-terminal of tau in
adults brain giving rise to a 4R (?10) isoform. 4R is absent
from mammals fetal brain, where the 3R (-10) isoform is
present [24]. In contrast to rodents, in adult humans both
isoforms (4R and 3R) are present in equal amounts [25].
Duetocontroversyconsideringtheinvolvementofdynein
heavy chain 1 mutation in pathogenesis of motor neuron
degeneration, in the present study we compared the changes
in the tau alternative mRNA splicing and in the total tau
expressionbetweentheSOD1G93Atransgenicmiceandthe
transgenic hybrid mice with the Dync1h1 (Cra1/?) and
double Dync1h1/SOD1G93A mutations (Cra1/SOD1).
Experimental Procedure
Mouse strain C57BL/6GJ-C3H/HeJ (B6-C3H) hybrids
harboring human Cu/Zn superoxide dismutase gene with
G93A amyotrophic lateral sclerosis-associated mutation
(SOD1/?), hybrids with mutation in dynein heavy chain 1
(Dync1h1; Cra1/?), and with double Dync1h1/SOD1G93A
mutation (Cra1/SOD1) were bred at the animal facility of
the University of Ulm, Germany. The SOD1G93A males
(B6 background; Jackson Laboratories, Ben Harbor, ME,
USA) were crossed with Cra1/? heterozygote female mice
(C3He background; Ingenium Pharmaceuticals AG, Mar-
tinsried, Germany), as described earlier by Teuchert et al.
(2006). Animals were at age of 70 days (presymptomatic
stages of the diseases for SOD1/? and Cra1/SOD1 groups),
140 days (presymptomatic stage for Cra1/? and symp-
tomatic for SOD1/? and Cra1/SOD1), and 365 days
(symptomatic stage for Cra1/?). Age- and genetic back-
ground-matched wild-type hybrid mice (?/?) were used as
controls. There were 6 males in each studied group. Frontal
cortex, spinal cord, hippocampus, and cerebellum were
isolated, stored at -80C, and used in the subsequent
experiments.
Total RNA was isolated from tissue samples according
to manufacturer’s protocol followed by reverse transcrip-
tion, polymerase chain reaction and DNA electrophoresis
in agarose gel. Reverse transcription reaction, the analysis
of alternative splicing of exons 2, 3 (N-terminal part of tau
protein) and exon 10 (C-terminal part) were performed, as
described earlier [26]. The expression of tau-mRNA iso-
forms was expressed as the ratio of optical density band of
tau isoform to optical density of 40 S ribosomal S12 pro-
tein RNA (housekeeping gene). Total tau-mRNA expres-
sion was expressed as a sum of 0, 1 and 2 N isoforms
expression. Each assay was repeated 2–4 times.
System UVI-KS4000, Syngen Biotechnology was used
for densitometric analysis of RT–PCR. Results were
expressed as means ± SD. Quantitative comparison
between studied groups was performed by Student’s t test
using Statistica 9.0 (StatSoft).
Studies were approved by the Ethic Committee for
Experiments on Animals at the Medical University of
Warsaw, Poland (no AO-KEZ/622/3/2008).
Results
Total Tau-mRNA Expression
The total tau-mRNA expression in frontal brain cortex of
wild-type (?/?) hybrids was 5.0 ± 0.5, 3.4 ± 0.4 and
3.0 ± 0.2 in mice age 70, 140 and 365 days, respectively
(Fig. 1). In hippocampus of 70-day-old mice it was similar
to the frontal cortex (4.8 ± 0.5), but in older groups it was
higher and accounted for 4.4 ± 0.3 and 5.9 ± 0.9, in mice
age 140 and 365 days, respectively (Fig. 1). The total tau-
mRNA expression in spinal cord of wild-type mice age 70
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123and 140 days was 3.5 ± 0.3 and 2.3 ± 0.2, and it was
similar as in cerebellum, where it accounted for 3.3 ± 0.7
and 2.5 ± 0.3, respectively (Fig. 1). In 365-days-old
groups it was 2.7 ± 0.2 and 4.0 ± 0.3, in spinal cord and
cerebellum, respectively (Fig. 1).
In frontal brain cortex of Cra1/? hybrids the total tau-
mRNA expression was 3.6 ± 0.7, 2.6 ± 0.5 and 2.3 ± 0.1
in 70-, 140- and 365-day-old mice, respectively. In each
age group it was signiﬁcantly lower than in age-matched
wild-type with P\0.001 for mice age 70 days, P\0.05
for 140-day-old, and P\0.001 for 365-day-old (Fig. 1). In
SOD1/? transgenics the expression was 5.5 ± 0.4 and
1.3 ± 0.2 in 70-day-old and 140-day-old group, respec-
tively, and it was signiﬁcantly decreased (P\0.001) only
in the older group (symptomatic stage of the disease). In
Cra1/SOD1 hybrids age 70 days, tau expression accounted
for 4.0 ± 08 and was signiﬁcantly lower than in wild-type
(P\0.005), whereas in the older group it was unchanged
(3.9 ± 0.7) (Fig. 1).
In hippocampus of Cra1/? and SOD1/? mice age
70 days tau expression was the same (4.1 ± 0.3) and it was
lower than in control groups (P\0.01), whereas in Cra1/
SOD1 hybrids it was unchanged (5.0 ± 0.6) (Fig. 1).
Among other groups, slight decrease in the total tau
expression was observed only in SOD1/? group age
140 days (P\0.01) (Fig. 1).
In spinal cord of 70-day-old Cra1/? hybrids the total
tau-mRNA expression was 3.1 ± 0.2, and it was slightly
lower (P\0.05) than in control group, whereas in older
mice it was unchanged (2.4 ± 0.2 in 140- and 2.8 ± 0.3 in
365-day-old mice) (Fig. 1). In SOD1/? group the total tau
expression was signiﬁcantly decreased only at presymp-
tomatic stage (3.0 ± 0.2, P\0.01). In Cra1/SOD1 mice it
was unchanged in group age 70 days, and higher than in
wild-type control in the group age 140 days (2.7 ± 0.1,
P\0.01) (Fig. 1).
In cerebellum of Cra1/? mice a slight increase in tau
expression was observed only at age 70 days (4.0 ± 0.4,
P\0.05), whereas in older groups the expression was
unchanged (2.9 ± 0.5 in 140-day-old mice, 4.0 ± 0.5 in
365-day-old mice) (Fig. 1). Differently than in Cra1/?
groups, in SOD1/? mice the total tau expression was sig-
niﬁcantly increased at both presymptomatic and symp-
tomatic stages reaching more than 180 and 240% of the
age-matched controls, respectively (6.1 ± 0.5 in 70-day-
old mice and 6.1 ± 0.7 in 140-day-old mice, P\0.001)
(Fig. 1). In Cra1/SOD1 transgenics the expression was also
increased but not so much, and it accounted for 4.3 ± 0.6
0
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Fig. 1 Total tau-mRNA
expression in various parts of
the central nervous system. The
total tau-mRNA was performed
as a sum of 0, 1 and 2 N
isoforms expression, and
expressed as a ratio of optical
density bands of all tau isoforms
to optical density of the
housekeeping gene, as indicated
in the Experimental Procedure
section. ﬁlled diamond dashed
lines—wild-type controls (?/
?); ﬁlled triangle—Cra1/?
transgenics; ﬁlled square—
SOD1/? transgenics; ﬁlled
circle—Cra1/SOD1 hybrides
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123in 70-day-old mice (P\0.01) and 3.4 ± 0.3 in 140-day-
old mice, P\0.01) (Fig. 1).
Alternative Splicing of Exons 2 and 3: Tau Isoforms
Expression in Frontal Cortex
In 70-day-old Cra1/? mice the expression of 0 and 1 N
isoforms-mRNA in frontal cortex was the same as in wild-
type control, and that of 2 N was signiﬁcantly lower
(P\0.001) (Fig. 2). In older, but still presymptomatic
Cra1/? group (age 140 days), the expression of 0 N form
was unchanged, 1 N was higher (P\0.05), but 2 N lower
(P\0.01) than in wild-type mice. In 365-day-old hybrids
(symptomatic stage) the expression of all isoforms was
signiﬁcantly lower than in wild-type mice (P\0.001,
0.05, 0.001 for 0, 1, 2 N, respectively). In SOD1/? hybrids
age 70 days, the expression of 0 and 1 N isoforms was
higher than in wild type mice (P\0.001), but the
expression of 2 N was much lower (P\0.001). In
140-day-old SOD1/? mice (symptomatic stage) all iso-
forms expression was signiﬁcantly lower (P\0.001) than
in control group. The proﬁle of tau-mRNA isoforms
expression in Cra1/SOD1 transgenics was partially like in
Cra1/? (0 N unchanged at age 70 and 140 days), and
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Fig. 2 Alternative splicing of
exons 2 and 3. The expression
of the 0, 1 and 2 N isoform-
mRNA was studied as indicated
in the Experimental Procedure
section. Black, solid bars; wild-
type contols (?/?); stripped
bares—Cra1/? mice; gray
bares—SOD1/? mice; dotted
bares—Cra1/SOD1 hybrides.
*changes statistically signiﬁcant
when compared with the wild-
type control
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123partially like in SOD1/? group (1 N increased at age
70 days, P\0.05). However, the expression of 2 N iso-
form in 140-day-old Cra1/SOD1 group was signiﬁcantly
increased (P\0.001), whereas in Cra1/? and SOD1/?
groups it was decreased (Fig. 2).
Tau Isoforms Expression in Hippocampus
In hippocampus of Cra1/? presymptomatic mice (age 70
and 140 days) there was a slight decrease in the expression
of 0 N and/or 2 N tau-mRNA isoforms (P\0.05), but at
symptomatic stage (age 365 days) the level of all isoforms
expression was unchanged (Fig. 2). In SOD1/? mice the
expression of 0 and 1 N isoforms in the 70-day-old group
(presymtomatic stage) and 1 N isoform in 140-day-old
group (symptomatic stage) was slightly decreased
(P\0.05) (Fig. 2). In 70-day-old group of Cra1/SOD1
mice, the 0 N expression was higher than in wild-type
(P\0.001), but in the older group (140-day-old), the
expression of 2 N was decreased (P\0.01) (Fig. 2).
Tau Isoforms Expression in Spinal Cord
In spinal cord of Cra1/? transgenic mice at presymptom-
atic stage, the expression of 2 and 0 N isoform was
decreased in younger (age 70 days) and older (age
140 days) group, respectively (P\0.05 and P\0.005),
whereas that of 1 N was increased in older mice
(P\0.001). At symptomatic stage (age 365 days), the 0 N
isoform expression was signiﬁcantly higher (P\0.001)
and 2 N lower (P\0.001) than in control group (Fig. 2).
In SOD1/? group age-70-days, the 1 and 2 N were
decreased (P\0.001 and 0.005, respectively), but in
group of age-140-days, the expression of 2 N was higher
(0.005) (Fig. 2). No differences on individual tau-mRNA
isoforms expression were observed between the wild-type
and transgenic mice in 70-day-old Cra1/SOD1 mice, but in
140-day-old group the expressions of 1 and 2 N were
increased (P\0.01 and 0.001, respectively) (Fig. 2).
Tau-mRNA Isoforms Expression in Cerebellum
In cerebellum of Cra1/? mice, the expression of tau-
mRNA isoforms was uniform in all studied groups (with
the exception of slightly higher 2 N in 70-day-old trans-
genics, P\0.01), and it was similar as in age matched
controls (Fig. 2). In SOD1/? mice, differently than in other
cns regions, the expression of all isoforms was much higher
than in control groups, at both presymptomatic and
symptomatic stages (P\0.001) (Fig. 2). In Cra1/SOD1
transgenics the expression of 0 and 1 N in 70-day-old mice
was also increased (P\0.05 and P\0.005), as well as
the expression of 1 and 2 N in 140-day-old group
(P\0.05 and P\0.005), however, the increase was not
as signiﬁcant as in SOD1/? groups (Fig. 2).
Alternative Splicing of Exon 10
The mRNA for exon 10 was present in all investigated
tissues of wild-type controls, Cra1/?, SOD1/? and Cra1/
SOD1 transgenics, at any studied age (Fig. 3).
Discussion
Tau is one of the main and most widely distributed
microtubule-associated proteins in the central nervous
system [27]. Mutations in the tau gene, located on chro-
mosome 17, are responsible for frontotemporal dementia
with parkinsonism (FTDP-17) indicating that tau dys-
function is sufﬁcient to cause neurodegeneration [28, 29].
Tau polymorphisms are genetic risk factors for sporadic
progressive supranuclear palsy (PSP) and corticobasal
degeneration (CBD) [30]. In some pathological conditions
tau protein undergoes post-translational modiﬁcations such
as phosphorylation, ubiquitination, glycosylation, glycation
[31–34]. Modiﬁed tau is an important component of neu-
roﬁbrillary tangles in Alzheimer’s disease, PSP, CDB,
amyotrophic lateral sclerosis-parkinsonism dementia com-
plex of Guam (ALS-G-PDC-G) and other tauopathies
[22, 25, 35]. Aberrant aggregates of tau have been docu-
mented in most of the neurodegenerative diseases with
ﬁlamentous inclusions [27, 36].
Amyotrophic lateral sclerosis (ALS) is the most dev-
astating condition among neurodegenerative diseases. The
majority of ALS cases are sporadic of still unknown eti-
ology and approximately 10% are familial [37]. Approxi-
mately 20% of familial ALS are associated with mutations
in the gene encoding for SOD1. However, the exact
mechanisms by which mutations in the SOD1 gene
Fig. 3 Exon 10 splice variants in frontal cortex age 140 days. Lanes
1, 8—molecular weight markers (50 and 123 bp, respectively); lanes
2–5 mice age 140 days: lane 2—wild-type, lane 3—Cra1/?, lane 4—
SOD1/?, lane 5—Cra1/SOD1; lines 7, 8—wild-type and Cra1/?
transgenics age 365 days, respectively
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123contribute to pathogenesis of ALS remain elusive [38].
Despite this fact, transgenic mice carrying a human mutant
SOD1 became an animal model for ALS [9, 39]. In our
previous studies we have indicated that the SOD1G93A
mutation inﬂuences alternative splicing and the total tau-
mRNA expression in a mouse central nervous system
(strain C57BL/6SJ) [26]. The changes were prominent in
frontal cortex, but not in hippocampus and spinal cord. In
frontal cortex at symptomatic stage of the disease, the level
of total tau mRNA was decreased by about 20%, mainly
because of 2 N isoform down-regulation [26, 40]. In the
present studies conducted on B6-C3H hybrids with the
SOD1G93A mutation (SOD1/?) the total tau expression in
frontal cortex at symptomatic stage was even lower
(decreased by more than 60%) and the level of all isoforms
was decreased, but especially that of 2 N (a threefold
decrease). The total tau-mRNA expression in frontal cortex
of mice with the Dync1h1 mutation (Cra1/? hybrids) was
also decreased but only by 25–30%. It was observed in all
Cra1/? groups, but was independent of their age and
clinical stage. In hippocampus and spinal cord of both
SOD1/? and Cra1/? transgenics slight changes were
observed only at presymptomatic stage (10–15%
decrease). Since hippocampus is not affected in ALS/
MND, the results obtained for SOD1/? transgenics are
understandable. However, the lack or only mild changes
observed in spinal cord, the structure primarily affected by
the neurodegenerative process, is puzzling. The changes in
tau expression are expected to occur mainly within the
motor neurons, which—unlike in the frontal cortex—form
only a small part of the spinal cord volume. When recal-
culating the results for the total tissue volume, the
observed changes may be too low to inﬂuence the ﬁnal
out-come. Detailed immunohistochemical studies could
potentially solve this question. Beside the possible method
limitations, the results leave open the question on the low
tau involvement in the degeneration of the alpha-motor
neurons bodies.
Practically no changes in the total tau-mRNA and its
isoforms expression in cerebellum of Cra1/? transgenics
were observed. Unlike in Cra1/? in SOD1/? mice the total
tau expression was almost 2- and over twofold higher at
presymptomatic and symptomatic SOD1/? hybrids,
respectively. The levels of all isoforms were elevated at
both stages. The present results are with agreement with
our earlier studies conducted on SOD1G93A mice (which
were not hybrids with C3H). We have shown that the level
of total tau-mRNA increases in cerebellum already in
newborns (by 25%) and it further rises with age reaching
the highest value at symptomatic stage (by 40%) due to
enhance of all isoforms expression [40]. Cerebellum is the
structure usually not studied in motor neuron diseases since
cerebellar dysfunction is not a clinical feature of ALS.
However, an increasing body of evidence shows the
involvement of extra-motor neuron regions in the pathol-
ogy of this disorder. Chung et al. [41, 42] detected the
presence of astrocytes immunoreactive for phosphorylated
extracellular signal-regulated kinases (pERK) and glyco-
gen synthase kinase (GSK) 3alpha involved in anti-apop-
totic signal transduction pathways in the spinal cord,
brainstem, central gray and cerebellar nuclei of symptom-
atic SODG93A transgenic mice. A recent neuropathologi-
cal study performed in humans with ALS showed neuronal
and glial TDP-43 pathology not only in cortical areas but
also in the nigro-striatal system and cerebellum [43]. The
above ﬁndings suggests that ALS does not selectively
affect the pyramidal motor system, but that it is a multi-
system neurodegenerative TDP-43 proteinopathy. The
functional MRI showed enhanced activation of bilateral
motor areas and ipsilateral cerebellum in response to task
performance in patients with ALS compared to healthy
controls. Performing the task resulted in additional acti-
vation of contralateral cerebellum and bilateral capsula
interna in ALS patients [44]. Another fMRI study suggests
that functional compensation following the degeneration of
cortical and spinal motor neurons in ALS leads to a
recruitment of subcortical motor structures, including
supplementary motor area, basal ganglia, brainstem, and
cerebellum [45]. Although the above results do no explain
the differences of tau expression between cerebellum and
the structures stereotypically involved in ALS pathogene-
sis, they indicate the presence of neural reorganization and
the possibility of functional compensation in this disease.
More research is needed to elucidate this phenomenon, the
more that our unpublished data indicate signiﬁcant changes
in the expression of some motor proteins in cerebellum
compared to brain cortex or spinal cord.
In Cra1/SOD1 double heterozygotes there were less
changes in individual isoforms tau expression than in Cra1/
? or SOD1/? transgenics. In frontal cortex the changes
resembled the results obtained in presymptomatic SOD1/?
group, whereas in hippocampus they looked rather like in
Cra1/? mice, at both presymptomatic and symptomatic
stages. Few changes in tau-mRNA isoforms expression
were noticed in spinal cord. In cerebellum, an increase in
tau isoforms was observed, but not as signiﬁcant as in
SOD1/? groups. The slight changes in tau-isoforms
expression resulted in unchanged total tau-mRNA levels or
lead to only mild changes (mainly in cerebellum). The lack
of tau expression changes in this model goes along with the
ﬁnding of Kieran et al. [10] who have shown the restoration
of retrograde transport in the double transgenic model. It
may at least partially explain better clinical condition and
longer survival time of mice carrying both dynein heavy
chain 1 and SOD1 mutations compared to those with the
SOD1 mutation alone [11].
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acids sequence at the N-terminal part of protein. The 2 N
isoform is the longest since it contains an insert of 58 amino
acid residues encoded by exons 2 and 3. The 1 N isoform
contains an insert of 29 amino acids encoded by exons 2,
and the shortest 0 N isoform does not contain products of
exons 2 and 3 [21]. N-terminal part of tau protein is
essential for tau function, since it is involved in signal
transduction pathways. It interacts with src-family tyrosine
kinases, phospholipase C-gamma isoenzymes, as well as
with other elements of cytoskeleton and neural plasma
membrane [24, 46, 47]. It is also crucial for the stabilization
and organization of axons and determining spacing between
their microtubules [48, 49]. Therefore, the alternative
splicing oftau exons 2and 3may alter the diameterof axons
[50]. The changes we observed, were most prominent in
frontal cortex and cerebellum of SOD1/? and, to a lower
extent, in Cra1/? transgenics. The big differences, espe-
cially in 2 N isoform-mRNA expression, at symptomatic
stage of Cra1/? and SOD1/? transgenics (about 75 and
30% decrease, respectively), as well as spectacular differ-
ences in all N-terminal isoforms expression in cerebellum
(no changes in Cra/? and dramatic increase in SOD1/?
mice) indicate distinct molecular mechanisms of dynein
heavy chain- and SOD1-induced motor neuron degenera-
tion. Since the role of its N-terminal forms individual tau
isoforms is not known, it is not easy to understand the
pathological consequences caused by the disturbances
observed in their expression. It is known that tau ﬁlaments,
but not monomeric soluble tau forms, selectively inhibit
anterograde (kinesin-dependent) fast axonal transport,
triggering the release of conventional kinesin from axo-
plasmic vesicles. LaPointe et al. [51] indicated that ﬁrst 18
amino acids at the N-terminus tau of squid axoplasm are
required to elicit the inhibitory effect of tau ﬁlaments on fast
axonal transport. The longest tau isoform (441 amino acids,
hTau40) shows greater propensity to form ﬁlaments than
the shorter ones [52]. Therefore, the increased expression of
all N-terminal isoforms in cerebellum but not in other cns
regions of SOD1/? transgenics may lead toformation of tau
aggregates. Till now little is known about the role of the
N-terminal tau domain in neuronal survival. The studies
conducted by Amadoro et al. [53] on adenovirally mediated
expression of tau’s N-terminal domains indicate, that the
exogenous overexpression of the N-terminal (1–230) as
well as full-length tau (1–441) inhibit the onset of apoptosis,
whereas the overexpression of the short fragment [1–44]
exerts a toxic effect leading to a necrotic-type death of
neurons. At present it is difﬁcult to say, whether the dis-
turbances in tau N-terminal isoforms-mRNA expression,
observed in our studies, are connected with higher (in brain
cortex) or lower (in cerebellum) sensitivity to SOD1-related
neurodegeneration.
Besides, Cra1 mice show defects in dynein complex
resulting in an impaired retrograde axonal transport [6–8].
This impairment may be due to tau dysfunction caused by
defective N-terminal alternative splicing, since the tau
N-terminal domain enhances the attachment of dynein/
dynactin complex to microtubules [19]. Such mechanism
may occur in brain cortex where, as we showed, the
expressionofallthreetauisoformsdecreasesatsymptomatic
stage, but not in cerebellum where it remains unchanged.
Thus, both Dync1h1 and SOD1G93A mutations cause
changes in tau-mRNA expression, which may subsequently
affect the structure of cytoskeleton and axonal transport.
However, clear differences between tau expression in Cra1/
? and SOD1/? transgenic animals indicate a distinct
pathogenic entity of these two conditions.
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